drugset / Trial / NCT07288528
A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
RandomizedFactorialOpen-labelTreatment
Summary
The FORTITUDE trial will provide head-to-head evidence on the benefits and harms of two commonly prescribed neuromodulators (low-dose morphine and pregabalin), the effectiveness of a virtual cough control therapy, exploratory assessment of potential synergy in combining these interventions, and the long-term outcomes of these treatments in patients with refractory or unexplained chronic cough.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2029-04-01
- Completion
- 2029-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Morphine | Other / unclassified | 5 mg | Oral |
| Subject | Pregabalin | Small molecule | 150 mg | Oral |